Cargando…
Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study
Thalassemia is the most common form of hereditary anemia. Here, we aimed to investigate the 13-year trend of the epidemiologic profiles and risk of comorbidities in thalassemia using a nationwide population-based registry in Korea. Diagnosis of thalassemia, the comorbidities and transfusion events i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104717/ https://www.ncbi.nlm.nih.gov/pubmed/35566415 http://dx.doi.org/10.3390/jcm11092289 |
_version_ | 1784707862494183424 |
---|---|
author | Lee, Jee-Soo Rhee, Tae-Min Jeon, Kibum Cho, Yonggeun Lee, Seung-Woo Han, Kyung-Do Seong, Moon-Woo Park, Sung-Sup Lee, Young Kyung |
author_facet | Lee, Jee-Soo Rhee, Tae-Min Jeon, Kibum Cho, Yonggeun Lee, Seung-Woo Han, Kyung-Do Seong, Moon-Woo Park, Sung-Sup Lee, Young Kyung |
author_sort | Lee, Jee-Soo |
collection | PubMed |
description | Thalassemia is the most common form of hereditary anemia. Here, we aimed to investigate the 13-year trend of the epidemiologic profiles and risk of comorbidities in thalassemia using a nationwide population-based registry in Korea. Diagnosis of thalassemia, the comorbidities and transfusion events in patients with thalassemia were identified in the Korean National Health Insurance database, which includes the entire population. The prevalence of thalassemia increased from 0.74/100,000 in 2006 to 2.76/100,000 in 2018. Notably, the incidence rate has nearly doubled in the last 2 years from 0.22/100,000 in 2016 to 0.41/100,000 in 2018. The annual transfusion rate gradually decreased from 34.7% in 2006 to 20.6% in 2018. Transfusion events in patients with thalassemia were significantly associated with the risk of comorbidities (diabetes: odds ratio [OR] = 3.68, 95% confidence interval [CI] = 2.59–5.22; hypertension: OR = 3.06, 95% CI = 2.35–4.00; dyslipidemia: OR = 1.72, 95% CI = 1.22–2.43; atrial fibrillation: OR = 3.52, 95% CI = 1.69–7.32; myocardial infarction: OR = 3.02, 95% CI = 1.09–8.38; stroke: OR = 3.32, 95% CI = 2.05–5.36; congestive heart failure: OR = 2.83, 95% CI = 1.62–4.97; end-stage renal disease: OR = 3.25, 95% CI = 1.96–5.37). Early detection of comorbidities and timely intervention are required for the management of thalassemia. |
format | Online Article Text |
id | pubmed-9104717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91047172022-05-14 Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study Lee, Jee-Soo Rhee, Tae-Min Jeon, Kibum Cho, Yonggeun Lee, Seung-Woo Han, Kyung-Do Seong, Moon-Woo Park, Sung-Sup Lee, Young Kyung J Clin Med Article Thalassemia is the most common form of hereditary anemia. Here, we aimed to investigate the 13-year trend of the epidemiologic profiles and risk of comorbidities in thalassemia using a nationwide population-based registry in Korea. Diagnosis of thalassemia, the comorbidities and transfusion events in patients with thalassemia were identified in the Korean National Health Insurance database, which includes the entire population. The prevalence of thalassemia increased from 0.74/100,000 in 2006 to 2.76/100,000 in 2018. Notably, the incidence rate has nearly doubled in the last 2 years from 0.22/100,000 in 2016 to 0.41/100,000 in 2018. The annual transfusion rate gradually decreased from 34.7% in 2006 to 20.6% in 2018. Transfusion events in patients with thalassemia were significantly associated with the risk of comorbidities (diabetes: odds ratio [OR] = 3.68, 95% confidence interval [CI] = 2.59–5.22; hypertension: OR = 3.06, 95% CI = 2.35–4.00; dyslipidemia: OR = 1.72, 95% CI = 1.22–2.43; atrial fibrillation: OR = 3.52, 95% CI = 1.69–7.32; myocardial infarction: OR = 3.02, 95% CI = 1.09–8.38; stroke: OR = 3.32, 95% CI = 2.05–5.36; congestive heart failure: OR = 2.83, 95% CI = 1.62–4.97; end-stage renal disease: OR = 3.25, 95% CI = 1.96–5.37). Early detection of comorbidities and timely intervention are required for the management of thalassemia. MDPI 2022-04-20 /pmc/articles/PMC9104717/ /pubmed/35566415 http://dx.doi.org/10.3390/jcm11092289 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Jee-Soo Rhee, Tae-Min Jeon, Kibum Cho, Yonggeun Lee, Seung-Woo Han, Kyung-Do Seong, Moon-Woo Park, Sung-Sup Lee, Young Kyung Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study |
title | Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study |
title_full | Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study |
title_fullStr | Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study |
title_full_unstemmed | Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study |
title_short | Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study |
title_sort | epidemiologic trends of thalassemia, 2006–2018: a nationwide population-based study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104717/ https://www.ncbi.nlm.nih.gov/pubmed/35566415 http://dx.doi.org/10.3390/jcm11092289 |
work_keys_str_mv | AT leejeesoo epidemiologictrendsofthalassemia20062018anationwidepopulationbasedstudy AT rheetaemin epidemiologictrendsofthalassemia20062018anationwidepopulationbasedstudy AT jeonkibum epidemiologictrendsofthalassemia20062018anationwidepopulationbasedstudy AT choyonggeun epidemiologictrendsofthalassemia20062018anationwidepopulationbasedstudy AT leeseungwoo epidemiologictrendsofthalassemia20062018anationwidepopulationbasedstudy AT hankyungdo epidemiologictrendsofthalassemia20062018anationwidepopulationbasedstudy AT seongmoonwoo epidemiologictrendsofthalassemia20062018anationwidepopulationbasedstudy AT parksungsup epidemiologictrendsofthalassemia20062018anationwidepopulationbasedstudy AT leeyoungkyung epidemiologictrendsofthalassemia20062018anationwidepopulationbasedstudy |